Stocks making the biggest moves midday: McDonald's, Cracker Barrel, Alibaba, Worthington & more

McDonald's fell more than 5% to its lowest level since 2022 after CEO Chris Kempczinski warned that elevated inflation and flat restaurant traffic will persist; U.S. same-store sales rose just 0.8% as domestic traffic declined. Paychex dropped nearly 7% on a Management Solutions revenue miss, Astrana Health lost 6% following a material data breach, and Immunovant fell 9% after disappointing lupus trial results prompted it to halt development in that indication. Offsetting gains included Cracker Barrel, up 5% on a revenue and margin beat, Worthington Enterprises, up 4% on data-center liquid-cooling tank demand, and IonQ, up 5% after testing a real-time quantum error decoder.

Analysis

The more investable signal is a bifurcation in lower-income consumer exposure rather than a broad restaurant call. MCD's traffic pressure and PAYX's softer Management Solutions result both point to a slowing small-business/household spending loop: franchisee labor deleveraging can restrain unit development, while weaker payroll-service growth is an early indicator of employment formation. Over the next 1-3 months, QSR names with less value-menu flexibility and higher franchisee leverage (JACK, WEN) are more exposed than CBRL, whose margin beat appears company-specific unless it is repeated by casual-dining peers.

WOR's data-center cooling-tank demand is a potentially underappreciated physical-infrastructure derivative of AI capex. Unlike GPU suppliers, specialized pressure-vessel capacity is qualified, domestic and constrained; sustained hyperscaler liquid-cooling deployments could support a multi-year mix uplift and reduce the cyclicality discount on WOR's industrial businesses. The key diligence item is backlog conversion and incremental margin disclosure at the next report; absent these, the move is a watch-list catalyst rather than evidence of a durable earnings reset.

RCL's acquisition creates a near-term multiple overhang because cash deployment and integration risk arrive well before the stated earnings contribution. The market may be underestimating the strategic value of controlling luxury land inventory and cross-selling to loyalty customers, but that value requires demand durability through 2027; any weakening in onboard revenue or booking curves would turn the deal into a leverage concern. In biotech, IMVT's readout increases the probability that its platform valuation must be supported by later indications, while ASTH's breach creates an unquantifiable remediation, litigation and customer-retention discount until scope is disclosed.

Key Decisions for Investors

• Initiate a 1-3 month relative-value short: short WEN or JACK versus long MCD in equal beta-weighted dollars. MCD's selloff likely prices traffic weakness faster than smaller QSR peers with less balance-sheet and franchisee support; cover if MCD's next U.S. traffic trend remains materially worse while WEN/JACK comp guidance is cut.
• Place WOR on a buy-on-confirmation alert rather than chase the initial move. Go long on evidence of data-center cooling backlog growth and segment-margin expansion at the next earnings release; target a 6-18 month rerating versus diversified industrial peers, with thesis invalidated by flat backlog or project delays from hyperscaler capex moderation.
• Maintain/establish a 3-6 month short RCL versus long CCL as a relative-value expression of transaction and financing uncertainty. Size modestly: the spread should widen if RCL's net leverage trajectory deteriorates or 2026 yield guidance softens; exit if management quantifies accretion earlier than expected or premium bookings accelerate.
• Avoid adding to IMVT until the Graves' disease program provides a clean efficacy and safety update. For existing exposure, reduce gross and retain only catalyst-sized optionality; further discontinuations, dose-limiting safety findings, or a cash runway falling below 18 months would invalidate a platform-recovery thesis.
• Monitor PAYX as a small-business labor leading indicator: a second consecutive Management Solutions revenue miss would support adding downside exposure through long ADP/short PAYX for the next two earnings cycles. The pair is falsified if PAYX reaccelerates client adds or payroll-hours trends while ADP decelerates.